Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. has successfully restructured its finances, converting nearly $29 million of debt into equity, thereby regaining full compliance with Nasdaq’s stockholders’ equity requirements. This strategic move, along with the launch of a new CDMO business unit, positions the biopharmaceutical company to enhance its focus on advancing its R&D programs. Scinai’s return to compliance also comes with a one-year Nasdaq monitoring period, ensuring sustained adherence to listing standards.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
